NEJM July 2026 Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
NEJM July 2026 Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
-
ナレーター：
-
著者：
This clinical study investigated whether patients with complex heart disease benefit from prolonging dual antiplatelet therapybeyond the standard one-year window following a stent procedure. By comparing a two-year regimen of combined medication against a single-drug approach, researchers discovered that the extended treatment significantly lowered the incidence of major cardiovascular events, such as strokes and heart attacks. Crucially, this longer therapeutic duration achieved better survival outcomes without increasing the danger of serious bleeding, a common concern with blood-thinning protocols. Ultimately, the trial suggests that for stable patients with multivessel disease, a more persistent medication schedule provides superior protection for long-term heart health.